High-Dose chemo combo shows promise for tough breast cancers

NCT ID NCT00066443

Completed Disease control Sponsor: NCIC Clinical Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving higher doses of two chemotherapy drugs (epirubicin and docetaxel) along with a drug to boost immune recovery (pegfilgrastim) could help women with advanced or inflammatory breast cancer. 93 women took part. The goal was to see how well the treatment worked and what side effects occurred. Results were shared at a major cancer conference.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm inflammatory breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Atlantic Health Sciences Corporation

Saint John, New Brunswick, E2L 4L2, Canada
CHA-Hopital Du St-Sacrement

Québec, Quebec, G1S 4L8, Canada
CancerCare Manitoba

Winnipeg, Manitoba, R3E 0V9, Canada
Odette Cancer Centre

Toronto, Ontario, M4N 3M5, Canada
Univ. Health Network-Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.